Knowledge, and attitude, and decisional conflict regarding biologics among patients with inflammatory bowel disease:
Qianqian Li1, Chenmei Xia1, Chunxiao Chen2
1Department of Gastroenterology, The First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou, China.
Objective:
This study aimed to investigate the knowledge, attitude, and decisional conflict regarding biologic treatments among patients with inflammatory bowel disease (IBD) in China.
Methods:
This cross-sectional study included IBD patients recruited at the authors' hospital between July 2023 and January 2024. Data were collected using a self-administered questionnaire covering demographic characteristics, knowledge, attitude, and decisional conflict (measured by the Decisional Conflict Scale).
Results:
A total of 405 IBD patients participated, with 45.9% aged 30-49 years and 64% male. The average knowledge score was 6.03 ± 2.98 (possible range: 0-11), and the average attitude score was 24.36 ± 3.32 (possible range: 8-40). Among them, 60 (14.8%) patients exhibited significant decisional conflict. Spearman correlation analysis revealed a positive association between knowledge and attitude scores (r = 0.554, p < 0.001). Multivariate analysis revealed that being ≥ 50 years old, having ulcerative colitis, never having used biologics, and experiencing significant decisional conflict were associated with lower knowledge scores. Higher knowledge scores, a monthly income between 10,000-20,000 RMB, never having used biologics, and significant decisional conflict were associated with lower attitude.
Conclusion:
Older age, ulcerative colitis, lack of prior biologic use, and decisional conflict were associated with lower knowledge and lower attitude toward biologics among IBD patients. Targeted educational interventions may help reduce decisional conflict and improve patients' attitudes toward biologic therapy.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...


